Public Company Healthcare

Gilead Sciences

Foster City, CA, United States

At Gilead, we set–and achieve—bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care.

Focus Areas
Biopharmaceuticals, Virology, Oncology
Website
www.gilead.com

Tracked deals

6

6 tracked deals across 2020-2026.

Recent pace

3

3 tracked deals announced in the last 12 months.

Deal mix

Buyout

5 buyout · 1 growth capital

Gilead Sciences Acquisition Volume by Year

Last 4 years

Acquisition volume by year Annual acquisition counts for the last 4 years for Gilead Sciences. 1 2020 1 2022 1 2023 ~4 est. 3 2026
Actual Full-year estimate

Supporting Data

Recent Transactions

  • Gilead Sciences to Acquire Tubulis (Up to $5.0B) to Expand ADC Oncology Pipeline
    April 7, 2026
    Buyer
    Gilead Sciences
    Target
    Tubulis
    Seller
    EQT Life Sciences (LSP 7 fund)
    Industry
    Biotechnology
    Location
    Germany
    Type
    Buyout

    Gilead Sciences entered into a definitive agreement to acquire Tubulis, a Munich-based clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), for $3.15 billion upfront in cash plus up to $1.85 billion in contingent milestone payments. Following completion, Tubulis will operate as a dedicated ADC research organization within Gilead, with the Munich site serving as a hub for ADC innovation.

  • Gilead Sciences and Lakefront Biotherapeutics Acquire Ouro Medicines
    March 27, 2026
    Buyer
    Gilead Sciences, Inc., Lakefront Biotherapeutics
    Target
    Ouro Medicines
    Industry
    Pharmaceuticals
    Location
    California, United States
    Type
    Buyout

    Gilead Sciences agreed to acquire Ouro Medicines to expand its inflammation and immunology pipeline with gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager for autoimmune diseases. The deal adds gamgertamig to Gilead’s portfolio and establishes Lakefront Biotherapeutics’ clinical development pipeline, with Lakefront overseeing Phase 1/2 studies and sharing upfront/milestone economics.

  • Gilead Sciences Acquires Arcellx for $7.8 Billion to Expand CAR T Cell Therapy Portfolio
    February 21, 2026
    Buyer
    Gilead Sciences
    Target
    Arcellx, Inc.
    Industry
    Healthcare Services
    Location
    California, United States
    Type
    Buyout

    Gilead Sciences entered into a definitive agreement to acquire Arcellx for $115 per share in cash plus a $5 per share contingent value right, implying an equity value of about $7.8 billion. The deal was completed on April 27, 2026, with Arcellx becoming a wholly owned subsidiary and full control of anito-cel and Arcellx’s D-Domain CAR technology platform.

  • Gilead Sciences Acquires XinThera
    May 9, 2023
    Buyer
    Gilead Sciences
    Target
    XinThera
    Seller
    Foresite Capital, OrbiMed Advisors, TTM Capital
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Buyout

    Gilead Sciences has acquired all outstanding shares of XinThera, a San Diego–based private biotechnology company, adding small-molecule oncology and inflammation programs (including PARP1-selective and MK2-targeting assets) to its early pipeline. Financial terms were not disclosed; XinThera was backed by investors including Foresite Capital, OrbiMed and TTM Capital.

  • Kite (Gilead) Enters Strategic Collaboration and Equity Investment in Arcellx to Co-develop and Co-commercialise CART-ddBCMA
    December 14, 2022
    Buyer
    Kite (a Gilead Company), Gilead Sciences, Inc.
    Target
    Arcellx, Inc.
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Growth capital

    Kite, a Gilead company, will make a $225 million upfront cash payment plus a $100 million equity investment in Arcellx to co-develop and co-commercialise Arcellx's lead CAR-T candidate, CART-ddBCMA, for relapsed or refractory multiple myeloma. The companies will share development and U.S. commercial economics (50/50 U.S. profits for co-commercialised products), with Kite responsible for manufacturing after technical transfer; ex-U.S. commercialization will be led by Kite with royalties to Arcellx.

  • Gilead Sciences Acquires Forty Seven for $4.9 Billion
    March 2, 2020
    Buyer
    Gilead Sciences, Inc.
    Target
    Forty Seven, Inc.
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Buyout

    Gilead Sciences agreed to acquire clinical-stage immuno-oncology company Forty Seven for $95.50 per share in cash, valuing the deal at approximately $4.9 billion. The acquisition adds Forty Seven's lead investigational antibody magrolimab to Gilead's oncology pipeline and is expected to close in Q2 2020 subject to customary approvals.

Related Acquisition Pages

Biotechnology Buyers & Acquisitions 4 tracked deals by Gilead Sciences. Healthcare Services Buyers & Acquisitions 1 tracked deal by Gilead Sciences. Pharmaceuticals Buyers & Acquisitions 1 tracked deal by Gilead Sciences. Acquisitions in California 5 tracked deals by Gilead Sciences.

Related articles

Selling a company? Get in front of buyers like Gilead Sciences

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →